Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00364377 · ClinicalTrials.gov registry record · Phase 4
Incretins in Impaired Fasting Glucose
A Phase 4 study of PreDiabetes, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT00364377: Completed Phase 4 study of PreDiabetes, sponsored by Mayo Clinic.
NCT00364377 is a Phase 4 study of PreDiabetes that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00364377, a Phase 4 study of PreDiabetes, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
People with high fasting glucose can develop type 2 diabetes with the passage of time. This study is being done to determine the effect of a novel medication in people with this elevated fasting glucose. Sitagliptin is a substance that raises levels of a hormone normally found in the blood. This hormone, called glucagon-like peptide-1 (GLP-1), is normally released by the intestine in response to the presence of food. This hormone acts like a messenger between the intestine and the pancreas to raise insulin levels, and therefore, lower blood sugars. Sitagliptin is effective in people with diabetes, however, this study is being done to determine if Sitagliptin is effective in people with high fasting glucose who do not yet have diabetes.
Primary Outcome
fasting glucose taken as the mean of blood glucose measured at -30, -20, -10 and 0 minutes prior to each inpatient meal study
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sitagliptin
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 4 |
What the finished NCT00364377 record still lists
NCT00364377 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (97% lower).
The record links to 1 condition, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00364377 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00364377 about?
NCT00364377 is a clinical study titled "Incretins in Impaired Fasting Glucose". People with high fasting glucose can develop type 2 diabetes with the passage of time. This study is being done to determine the effect of a novel medication in people with this elevated fasting glucose. Sitagliptin is a substance that raises levels of a hormone normally found in the blood. This hor...
What is the current status of trial NCT00364377?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2006-08. Estimated completion is 2008-12.
What conditions does trial NCT00364377 study?
This clinical trial studies the following conditions: PreDiabetes.
What interventions are being tested in trial NCT00364377?
The interventions under investigation include: Placebo (OTHER), Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT00364377?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00364377 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00364377's enrollment target sits among peer trials
22 131st of 149 higher than 18 of 149 other PreDiabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
RECRUITING · Phase 4
-
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
RECRUITING · Phase 4
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans
ACTIVE NOT RECRUITING · Phase 4
-
Use of Empagliflozin to Treat Prediabetes
ACTIVE NOT RECRUITING · Phase 4
-
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia